Realizing Promise of
Novel, Dynamically
Re-Thinking the Role of Immunomodulators: Dynamic Dual Action READ MORE » Seeking Balance
in COVID-19
Immune Storms

LATEST NEWS: November 7, 2023

EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613

logo logo

MONTVALE, NJ –November 7, 2023 —EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”) today provides an update on its clinical program for its lead drug candidate EOM613. EOM613 is a peptide-nucleic acid-based broad spectrum immune regulating agent that acts on both key pro-inflammatory and anti-inflammatory cytokines with potential therapeutic utility in treating a variety of acute and chronic inflammatory conditions.


This agent has been previously shown to regulate cytokine expression in a variety of immune cells in cell culture, and more recently in a Phase 1/2a human clinical trial in patients hospitalized COVID-19 with cytokine-driven respiratory inflammation. Recently reported results of this trial, named RESCUE, indicated marked beneficial reductions of the soluble interleukin-2 receptor protein (sIL-2R) cytokine levels in treated patients, with a concomitant mitigation of the release of the pro-inflammatory cytokine tumor necrosis factor alpha (TNF-alpha).



Our Mission

To rescue, repair, and restore health in patients suffering
from debilitating and sometimes deadly diseases

Our Values

Power science
Strive relentlessly
Support each other and humankind

Read More »

Rescue, Repair, and Restore

EOM Pharmaceuticals’ goal is to rescue, repair, and restore health. We are focused on developing novel drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases.

Rethinking the Role of Immunomodulators
Watch how EOM Pharmaceuticals is rethinking the role of immunomodulators with its novel, dynamically dual-acting, broad-spectrum lead asset, EOM613, which can produce anti- and pro-inflammatory effects and could mitigate a hyperimmune reaction or “cytokine storm.”

Our Pipeline


An investigational, novel, dynamically dual-acting immunomodulator. EOM613 is a peptide-nucleic acid solution and is believed to have both anti-inflammatory and pro-inflammatory broad-spectrum cytokine effects. In human cell culture studies, EOM613 demonstrated a unique “dynamic dual action” by suppressing or stimulating monocytes and macrophages depending on the activation state and environment of those key immune cells.1,2,3 It is hypothesized that this dynamic dual action may overcome a limitation of many approved immunomodulators that only reduce the inflammatory state, without achieving immune system balance.


An investigational, broad-spectrum aminosterol with a unique intracellular mechanism for the treatment of retinal diseases. EOM147 is believed to affect multiple angiogenic growth factors such as VEGF, PdGF, and bFGF. This mechanism of action is uniquely differentiated from other retinal therapies that are only anti-VEGF and administered as an intraocular injection. The novel formulation, administererd as an eye drop, represents a potential breakthrough that does not require intraocular injection.

EOM147 is being developed as proprietary, newly reformulated eye drop, containing a steroid-polyamine conjugate compound with broad-spectrum antimicrobial activity and anti-angiogenic activity.

News Highlights

News Highlights launching soon